WORCESTER, Mass. and TORONTO, June 6, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) (www.generex.com) today announced that the Company, together with Global Medical Direct, Inc. ("GMD") and its stockholders, have mutually decided not to proceed with the Company's previously announced acquisition of a 51% interest in GMD.
(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b)
Generex management and its Board of Directors have concluded that it will be in the best interests of the Company and its stockholders to devote the Company's financial resources to the Company's extant and planned clinical and regulatory initiatives, including Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, and the recently announced diabetes research and development collaboration with Amarantus BioSciences, Inc.
GMD and its stockholders are fully supportive of Generex in this respect and have agreed to waive payment of the transaction break fee.
"Although we see significant synergies between Generex and GMD, the timing is not yet ripe for both companies to realize significant benefits from those synergies," commented Dr. David Brusegard, the Generex Chief Operating Officer. "We have an outstanding relationship with GMD management and hope to continue to work with them as a distributor of Generex Oral-lyn™."
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases. Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy. One of its platform technologies relies on inhibition of expression of the Ii protein. Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. Risks and uncertainties relating to the proposed dividend include the risks that: (1) Generex and Amarantus do not reach a definitive agreement; (2) Generex will not obtain the stockholder approval of the reverse stock split; (3) Generex will not meet the standards for listing its common stock on a national stock exchange; (4) Amarantus will be unable to have a registration statement declared effective; (5)the trading price of Amarantus shares declines after a definitive agreement is signed and (6) the market for Amarantus shares is adversely affected by the dividend. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials or ultimate regulatory approval cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials or when it will obtain ultimate regulatory approval by a particular regulatory agency. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
SOURCE Generex Biotechnology Corporation
Share this article